We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bacteriophage-Based Blood Test Rapidly Detects TB Bacteria

By LabMedica International staff writers
Posted on 15 Jul 2019
A blood test based on bacteriophage that infect living Mycobacterium tuberculosis (Mtb) bacteria has been shown to diagnose human tuberculosis (TB) and may be able to predict which patients with latent tuberculosis will progress to the active form of the disease.

It is difficult to diagnosis tuberculosis through traditional culture of the slow growing Mtb. More...
Molecular tests to detect Mtb DNA are of limited value due to the organisms’ cell wall, which complicates DNA extraction. The new PBD Biotech (Suffolk, United Kingdom) Actiphage test uses a specific bacteriophage that infects live Mtb and ruptures the cells to release DNA. The DNA is then analyzed by PCR. The whole testing process can be completed in as little six hours.

Investigators at Leicester Biomedical Research Centre (United Kingdom) and the University of Nottingham (United Kingdom) used the Actiphage test to study 66 subjects who were separated into four groups: those with active pulmonary TB, those with latent TB, a control group of patients referred for suspected TB but found not to have the disease, and a control group of healthy individuals. The subjects were tested for Mtb twice, 12 months apart.

Results of Actiphage testing revealed positive findings for 73% of subjects who were subsequently diagnosed with TB. None of the participants in the control groups tested positive with Actiphage, and none of the patients with latent TB who tested negative with Actiphage went on to develop active TB.

The finding that two of the three subjects with latent TB infection who tested positive with Actiphage went on to develop the active form of the disease more than six months later, suggested that the test may have a predictive role in identifying people with the infection at risk of developing the disease.

“TB is the leading cause of death from an infectious disease. It most commonly affects the lungs and from this site is transmitted to others by coughing and sneezing. As there is a lack of diagnostic tools for people unable to bring up sputum, diagnosis is delayed, increasing the likelihood that the disease is spread,” said senior author Dr. Pranabashis Haldar, clinical senior lecturer at the University of Leicester. “Our observations provide new insights into how human TB develops and support recent evidence of the existence of a transitional state of TB infection called incipient TB that does not produce symptoms but carries a high risk of progressing to active TB. There is potential for Actiphage to be developed, both as a mainstream blood test to diagnose TB and as a test used in screening programs to help us identify and treat people with latent infection.”

The study was published in the June 22, 2019, online edition of the journal Clinical Infectious Diseases.

Related Links:
PBD Biotech
Leicester Biomedical Research Centre
University of Nottingham


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.